核苷(酸)类似物停药后肝功能失代偿的发生率:来自慢性乙型肝炎患者的大型国际多民族队列(RETRACT-B研究)结果
这项国际多中心队列研究纳入1,557例病毒抑制、治疗结束时HBeAg阴性的慢性乙型肝炎患者,分析停用核苷(酸)类似物后肝功能失代偿的发生率。中位随访60个月时,总队列和≥12个月巩固治疗的非肝硬化亚组的累积发生率分别为1.8%和1.1%;肝硬化患者(HR 5.08)和治疗开始时HBeAg阳性患者(HR 5.23)的失代偿风险更高。
要点
- 停药后60个月肝功能失代偿累积发生率总队列为1.8%,非肝硬化巩固治疗≥12个月亚组为1.1%。
- 肝硬化患者停药后失代偿风险显著升高(HR 5.08,P<0.001)。
- 治疗开始时HBeAg阳性患者失代偿风险亦升高(HR 5.23,P<0.001),亚组中HR 10.5。
核心结论
- 肝硬化患者和治疗开始时HBeAg阳性的患者在停用核苷(酸)类似物前应仔细评估,以预防肝功能失代偿。
- 停药后频繁监测病毒学和宿主动力学对判断患者结局至关重要。
研究设计与样本
- 国际多中心队列研究,纳入1,557例病毒抑制、治疗结束时HBeAg阴性的慢性乙型肝炎患者,均已停用核苷(酸)类似物。
- 采用生存分析技术分析停药后肝功能失代偿率及按患者特征分组的差异。
- 另分析一个亚组:非肝硬化且停药前巩固治疗≥12个月的患者(n=1,289)。
- 肝功能失代偿判定为与停药相关:停药期间诊断或重新开始治疗后6个月内诊断。
主要发现
- 总队列中11.8%诊断肝硬化,84.2%治疗开始时HBeAg阴性;停药后20例发生肝功能失代偿,其中亚组10例。
- 停药60个月时肝功能失代偿累积发生率:总队列1.8%,亚组1.1%。
- 肝硬化患者肝功能失代偿率更高(HR 5.08,P<0.001)。
- 治疗开始时HBeAg阳性患者肝功能失代偿率更高(HR 5.23,P<0.001)。
- 治疗开始时HBeAg状态与肝功能失代偿的关联在亚组中仍显著(HR 10.5,P<0.001)。
临床怎么用
- 肝硬化患者和治疗开始时HBeAg阳性的患者在停用核苷(酸)类似物前应仔细评估,以预防肝功能失代偿。
- 停药后频繁监测病毒学和宿主动力学对判断患者结局至关重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite improvements in the management of chronic hepatitis B (CHB), risk of cirrhosis and hepatocellular carcinoma remains. While hepatitis B surface antigen loss is the optimal end point, safe discontinuation of nucleos(t)ide analog (NA) therapy is controversial because of the possibility of severe or fatal reactivation flares. METHODS: This is a multicenter cohort study of virally suppressed, end-of-therapy (EOT) hepatitis B e antigen (HBeAg)-negative CHB patients who stopped NA therapy (n = 1,557). Survival analysis techniques were used to analyze off-therapy rates of hepatic decompensation and differences by patient characteristics. We also examined a subgroup of noncirrhotic patients with consolidation therapy of ≥12 months before cessation (n = 1,289). Hepatic decompensation was considered related to therapy cessation if diagnosed off therapy or within 6 months of starting retreatment. RESULTS: Among the total cohort (11.8% diagnosed with cirrhosis, 84.2% start-of-therapy HBeAg-negative), 20 developed hepatic decompensation after NA cessation; 10 events were among the subgroup. The cumulative incidence of hepatic decompensation at 60 months off therapy among the total cohort and subgroup was 1.8% and 1.1%, respectively. The hepatic decompensation rate was higher among patients with cirrhosis (hazard ratio [HR] 5.08, P < 0.001) and start-of-therapy HBeAg-positive patients (HR 5.23, P < 0.001). This association between start-of-therapy HBeAg status and hepatic decompensation remained significant even among the subgroup (HR 10.5, P < 0.001). DISCUSSION: Patients with cirrhosis and start-of-therapy HBeAg-positive patients should be carefully assessed before stopping NAs to prevent hepatic decompensation. Frequent monitoring of viral and host kinetics after cessation is crucial to determine patient outcome.
引用
- Hirode G, Hansen BE, Chen CH, et al. Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study). Am J Gastroenterol. 2023. PMID: 36719174. doi:10.14309/ajg.0000000000002203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。